MétaCan
Menu
← Back to cohort
Record W4416140285 · doi:10.1093/neuonc/noaf201.1031

PATH-79. High-grade astrocytoma with piloid features (HGAP) comprehensive update: histological grading, molecular markers and clinical outcomes

2025· article· en· W4416140285 on OpenAlexaff
Shuodan Zhang, Omkar Singh, Karen Dazelle, Zied Abdullaev, Patrick J. Cimino, Calixto‐Hope G. Lucas, Sahara Cathcart, Christopher Mount, Nelli S. Lakis, Peter Pytel, Vanessa Goodwill, Robert Macaulay, William C. McDonald, Roberta Seidman, Matthew D. Wood, Krishna Bharani, Janna H. Neltner, Hope Richard, Koping Chang, Linda J. Szymanski, Stephen Yip, Abir Mukherjee, Osório Lopes Abath Neto, Suash Sharma, Richard Green, Daniel Brown, Maria A. Gubbiotti, Jennifer Eschbacher, Murat Gökden, Cristina Vincentelli, William H. Yong, Julieann C. Lee, Kenneth Aldape

Bibliographic record

VenueNeuro-Oncology · 2025
Typearticle
Languageen
FieldMedicine
TopicGlioma Diagnosis and Treatment
Canadian institutionsVancouver General Hospital
Fundersnot available
KeywordsATRXHistopathologyCohortImmunohistochemistryProgression-free survivalAstrocytomaNeurofibromatosisCDKN2A

Abstract

fetched live from OpenAlex

Abstract BACKGROUND HGAP was first described in 2018. However, prognostic factors of clinical outcome are not well-understood secondary to recent recognition and paucity of data for this diagnostic entity. Here, we utilize a large HGAP cohort (n=252) to survey the genomic landscape and explore prognostic correlates. METHODS NIH DNA methylation profiling was performed to identify HGAP cases and combined with publicly available datasets. Evaluable molecular markers, patient demographics, tumor location, imaging reports, treatment history (e.g. temozolomide, targeted therapy, surgery, and radiation) and survival data were assessed. Kaplan-Meier analysis was performed. RESULTS The cohort included cases that matched to HGAP on the NIH/Bethesda methylation classifier at ≥0.9 confidence score. More males (60%) than females (40%) were in the cohort. Twenty-one percent of patients were known to have neurofibromatosis type 1. Posterior fossa location was predominant (57%, n=131). Common genomic findings included alterations in NF1 (58%), ATRX (50%), FGFR1 (15%), TP53 (9%) and PIK3CA (8%). CDKN2A/B homozygous deletion was identified in 80% of cases. MGMT promoter methylation was found in 55% of cases. Median progression free survival (mPFS) was 24 months (mo), and median overall survival (mOS) was 108 mo. Central histological review revealed 67% of cases were high-grade. High-grade histopathology (brisk mitotic activity) was not associated with survival. Immunohistochemical ATRX loss was associated with shorter mPFS (18.0 mo vs 35.5 mo, p=0.04) and mOS (93.7 mo vs not reached, p=0.04). The presence of ATRX genetic alterations was associated with shorter mOS (30 mo vs not reached, p=0.008). CDKN2A/B homozygous deletion and MGMT status were not correlative with patient outcome. CONCLUSION HGAP is a glial neoplasm that shows frequent tumor recurrence. The majority of HGAP cases are high-grade. Our analysis of correlates with patient outcome suggests immunohistochemical ATRX loss and molecular ATRX alteration may be important poor prognostic markers.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.001
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.006
Threshold uncertainty score0.011

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0010.001
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.000
Bibliometrics0.0020.002
Science and technology studies0.0000.000
Scholarly communication0.0010.001
Open science0.0010.001
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0020.002

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.019
GPT teacher head0.325
Teacher spread0.306 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2025
Admission routes1
Has abstractyes

Explore more

Same venueNeuro-Oncology→Same topicGlioma Diagnosis and Treatment→French-language works237,207→